DLBCL (Diffuse Large B Cell Lymphoma),Lymphoma,MCL (Mantle Cell Lymphoma) Pirtobrutinib Found Safe And Effective In cBTKi Pre‑Treated MCL Nov 03, 2023
DLBCL (Diffuse Large B Cell Lymphoma),Lymphoma Tafasitamab Shows Five‑Year Efficacy And Safety In R/R DLBCL Patients Nov 02, 2023
DLBCL (Diffuse Large B Cell Lymphoma),FL (Follicular Lymphoma),Lymphoma Epcoritamab + R-CHOP Found Effective & Safe in 1st-Line High-Risk DLBCL Oct 23, 2023
DLBCL (Diffuse Large B Cell Lymphoma),FL (Follicular Lymphoma),Lymphoma Epcoritamab With Rituximab + R2 Show Durable Responses In High-risk FL Patients Oct 17, 2023
DLBCL (Diffuse Large B Cell Lymphoma),FL (Follicular Lymphoma),Lymphoma,MCL (Mantle Cell Lymphoma),MZL (Marginal Zone Lymphoma) Subcutaneous Epcoritamab Is Well-Tolerated And Effective In Patients With R/R LBCL Oct 05, 2023
DLBCL (Diffuse Large B Cell Lymphoma),FL (Follicular Lymphoma),Lymphoma,MCL (Mantle Cell Lymphoma),MZL (Marginal Zone Lymphoma) Epcoritamab Shows Lasting Remissions in R/R LBCL Patients Oct 04, 2023
DLBCL (Diffuse Large B Cell Lymphoma),Lymphoma ITMTX Vs IVMTX For CNS Relapse In High-Risk DLBCL Sep 27, 2023
DLBCL (Diffuse Large B Cell Lymphoma),FL (Follicular Lymphoma),Lymphoma Epcoritamab + R2 Regimen Improves Outcomes In Patients With High‑Risk Follicular Lymphoma Sep 26, 2023